{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T22:46:51Z","timestamp":1770331611436,"version":"3.49.0"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T00:00:00Z","timestamp":1670198400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["One Health"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.onehlt.2022.100470","type":"journal-article","created":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T13:34:21Z","timestamp":1670333661000},"page":"100470","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Determining the acceptability of a novel One Health vaccine for Rift Valley Fever prior to phase II\/III clinical trials in Uganda"],"prefix":"10.1016","volume":"16","author":[{"given":"Alexander","family":"Bowmer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Ssembatya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Okot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Bagyenyi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen Venny","family":"Rubanga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gladys","family":"Kalema-Zikusoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.onehlt.2022.100470_bb0005","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1086\/378747","article-title":"Rift Valley fever epidemic in Saudi Arabia: epidemiological, clinical, and laboratory characteristics","volume":"37","author":"Madani","year":"2003","journal-title":"Clin. Infect. Dis."},{"issue":"2 Suppl","key":"10.1016\/j.onehlt.2022.100470_bb0010","doi-asserted-by":"crossref","first-page":"22","DOI":"10.4269\/ajtmh.2010.09-0318","article-title":"Epidemiologic and clinical aspects of a Rift Valley fever outbreak in humans in Tanzania, 2007","volume":"83","author":"Mohamed","year":"2010","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.onehlt.2022.100470_bb0015","author":"WHO"},{"issue":"6","key":"10.1016\/j.onehlt.2022.100470_bb0020","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/0035-9203(79)90005-1","article-title":"The Rift Valley fever epizootic in Egypt 1977-78. 2. Ecological and entomological studies","volume":"73","author":"Hoogstraal","year":"1979","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"issue":"2","key":"10.1016\/j.onehlt.2022.100470_bb0025","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0005383","article-title":"The one Health approach to identify knowledge, attitudes and practices that affect community involvement in the control of Rift Valley fever outbreaks","volume":"11","author":"Hassan","year":"2017","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.onehlt.2022.100470_bb0030","series-title":"Uganda Virus Research Institute","article-title":"One-health ChAdOx1 RVF phase I vaccine clinical trial","author":"Anywaine","year":"2021"},{"key":"10.1016\/j.onehlt.2022.100470_bb0035","first-page":"28024","article-title":"A systematic review of Rift Valley Fever epidemiology 1931-2014","volume":"5","author":"Nanyingi","year":"2015","journal-title":"Infect. Ecol. Epidemiol."},{"issue":"1","key":"10.1016\/j.onehlt.2022.100470_bb0040","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0009852","article-title":"Paving the way for human vaccination against Rift Valley fever virus: a systematic literature review of RVFV epidemiology from 1999 to 2021","volume":"16","author":"Gerken","year":"2022","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.onehlt.2022.100470_bb0045","series-title":"SSHAP Case Study Issue 4","article-title":"Fever: Local Knowledge, Health-Seeking Behaviours and Attitudes Towards Vaccination in Southern Uganda","author":"Bowmer","year":"2020"},{"key":"10.1016\/j.onehlt.2022.100470_bb0050","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.coviro.2018.02.001","article-title":"Rift Valley fever vaccines: current and future needs","volume":"29","author":"Dungu","year":"2018","journal-title":"Curr. Opin. Virol."},{"issue":"3","key":"10.1016\/j.onehlt.2022.100470_bb0055","article-title":"Current status of Rift Valley Fever vaccine development","volume":"5","author":"Faburay","year":"2017","journal-title":"Vaccines (Basel)"},{"issue":"6","key":"10.1016\/j.onehlt.2022.100470_bb0060","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1080\/14760584.2017.1321482","article-title":"Rift Valley fever vaccines: an overview of the safety and efficacy of the live-attenuated MP-12 vaccine candidate","volume":"16","author":"Ikegami","year":"2017","journal-title":"Expert Rev. Vaccines"},{"issue":"12","key":"10.1016\/j.onehlt.2022.100470_bb0065","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1080\/14712598.2019.1662784","article-title":"Candidate vaccines for human Rift Valley fever","volume":"19","author":"Ikegami","year":"2019","journal-title":"Expert. Opin. Biol. Ther."},{"key":"10.1016\/j.onehlt.2022.100470_bb0070","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.antiviral.2014.03.008","article-title":"One Health approach to Rift Valley fever vaccine development","volume":"106","author":"Kortekaas","year":"2014","journal-title":"Antivir. Res."},{"key":"10.1016\/j.onehlt.2022.100470_bb0075","doi-asserted-by":"crossref","first-page":"20617","DOI":"10.1038\/srep20617","article-title":"Chimpanzee adenovirus vaccine provides multispecies protection against Rift Valley Fever","volume":"6","author":"Warimwe","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.onehlt.2022.100470_bb0080","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/s41541-019-0138-0","article-title":"Safety and efficacy of ChAdOx1 RVF vaccine against Rift Valley fever in pregnant sheep and goats","volume":"4","author":"Stedman","year":"2019","journal-title":"NPJ Vaccines"},{"issue":"6","key":"10.1016\/j.onehlt.2022.100470_bb0085","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1007\/s10806-015-9574-7","article-title":"One Health, vaccines and Ebola: the opportunities for shared benefits","volume":"28","author":"Capps","year":"2015","journal-title":"J. Agric. Environ. Ethics"},{"issue":"1","key":"10.1016\/j.onehlt.2022.100470_bb0090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3201\/eid1601.081467","article-title":"Public health threat of new, reemerging, and neglected zoonoses in the industrialized world","volume":"16","author":"Cutler","year":"2010","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.onehlt.2022.100470_bb0095","series-title":"Preventing the Next Pandemic: Zoonotic Diseases and how to Break the Chain of Transmission","author":"Institute, U.N.E.P.a.I.L.R","year":"2020"},{"issue":"2","key":"10.1016\/j.onehlt.2022.100470_bb0100","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1093\/infdis\/170.2.265","article-title":"Dynamics of emergence","volume":"170","author":"Krause","year":"1994","journal-title":"J. Infect. Dis."},{"issue":"5","key":"10.1016\/j.onehlt.2022.100470_bb0105","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1086\/513494","article-title":"Potential for Ebola transmission between gorilla and chimpanzee social groups","volume":"169","author":"Walsh","year":"2007","journal-title":"Am. Nat."},{"issue":"7","key":"10.1016\/j.onehlt.2022.100470_bb0110","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1000536","article-title":"Isolation of genetically diverse Marburg viruses from Egyptian fruit bats","volume":"5","author":"Towner","year":"2009","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.onehlt.2022.100470_bb0115","series-title":"SSHAP Practical Approaches Brief 6","article-title":"Social science research for vaccine deployment in epidemic outbreaks","author":"Bowmer","year":"2020"},{"key":"10.1016\/j.onehlt.2022.100470_bb0120","series-title":"Clinical and Vaccine Trials for COVID-19: Key Considerations from Social Science, S.S.i.H. Action, Editor","author":"Burns","year":"2020"},{"issue":"7","key":"10.1016\/j.onehlt.2022.100470_bb0125","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1080\/21645515.2018.1459252","article-title":"Measuring trust in vaccination: a systematic review","volume":"14","author":"Larson","year":"2018","journal-title":"Hum. Vaccin. Immunother."},{"issue":"9790","key":"10.1016\/j.onehlt.2022.100470_bb0130","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/S0140-6736(11)60678-8","article-title":"Addressing the vaccine confidence gap","volume":"378","author":"Larson","year":"2011","journal-title":"Lancet"},{"issue":"19","key":"10.1016\/j.onehlt.2022.100470_bb0135","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1016\/j.vaccine.2014.01.081","article-title":"Understanding vaccine hesitancy around vaccines and vaccination from a global perspective: a systematic review of published literature, 2007-2012","volume":"32","author":"Larson","year":"2014","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.onehlt.2022.100470_bb0140","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1080\/21645515.2016.1243633","article-title":"Vaccine hesitancy and health literacy","volume":"13","author":"Biasio","year":"2017","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.onehlt.2022.100470_bb0145","series-title":"Catalogue of Interventions Addressing Vaccine Hesitancy","author":"Control, E.C.f.D.P.a","year":"2017"},{"issue":"44","key":"10.1016\/j.onehlt.2022.100470_bb0150","doi-asserted-by":"crossref","first-page":"6457","DOI":"10.1016\/j.vaccine.2018.08.031","article-title":"Strategies to increase vaccine acceptance and uptake: from behavioral insights to context-specific, culturally-appropriate, evidence-based communications and interventions","volume":"36","author":"Thomson","year":"2018","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.onehlt.2022.100470_bb0155","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1086\/266350","article-title":"The influence of source credibility on communication effectiveness*","volume":"15","author":"Hovland","year":"1951","journal-title":"Public Opin. Q."},{"issue":"1","key":"10.1016\/j.onehlt.2022.100470_bb0160","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1027\/1016-9040\/a000169","article-title":"The role of public trust during pandemics: implications for crisis communication","volume":"19","author":"Siegrist","year":"2014","journal-title":"Eur. Psychol."},{"issue":"2","key":"10.1016\/j.onehlt.2022.100470_bb0165","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/s41591-020-1124-9","article-title":"A global survey of potential acceptance of a COVID-19 vaccine","volume":"27","author":"Lazarus","year":"2021","journal-title":"Nat. Med."}],"container-title":["One Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352771422001021?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352771422001021?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T04:06:05Z","timestamp":1762488365000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352771422001021"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":33,"alternative-id":["S2352771422001021"],"URL":"https:\/\/doi.org\/10.1016\/j.onehlt.2022.100470","relation":{},"ISSN":["2352-7714"],"issn-type":[{"value":"2352-7714","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Determining the acceptability of a novel One Health vaccine for Rift Valley Fever prior to phase II\/III clinical trials in Uganda","name":"articletitle","label":"Article Title"},{"value":"One Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.onehlt.2022.100470","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"100470"}}